ZYLOXTB (02190) releases annual performance with a net profit of 244 million yuan, representing a year-on-year increase of 143.75%.

ZYLOXTB (02190) announced its annual performance for the year ending December 31, 2025. The group achieved revenue of 1.057 billion yuan, an increase of 35.15% compared to the previous year; gross profit of 763 million yuan, an increase of 36.26%; net profit of 244 million yuan, an increase of 143.75%; and basic earnings per share of 0.7646 yuan. The group plans to distribute a final dividend of 0.22 yuan per share. The announcement stated that during the reporting period, the group's revenue increased by 35.15% compared to 2024. 64.1% of the group's product revenue came from neurovascular intervention products business, while 35.9% came from peripheral vascular intervention products business. The significant increase in revenue was mainly attributed to the rapid growth in sales of neurovascular and peripheral vascular intervention devices. In 2025, sales revenue of neurovascular intervention products increased by 28.0% compared to 2024, mainly due to the promotion and rapid penetration of relatively new approved products such as the Qilin blood flow guiding device nationwide, benefiting from the execution of centralized procurement in approximately 30 provinces nationwide; significant revenue growth of major mature products such as the Yinshe intracranial intermediate catheter series, Feng intracranial aneurysm embolization spring coils, and neurovascular guide wires; and the group's continuous efforts to improve the penetration rate of products in hospitals at all levels. In 2025, sales revenue of peripheral vascular intervention products increased by 50.3% compared to 2024, mainly due to the group's continuous efforts to expand market access, increase hospital penetration rate, and expand distribution network, leading to rapid growth in sales revenue of mature products such as the UltraFree drug-coated PTA balloon dilatation catheter (UltraFree DCB), Phoenix peripheral detachable woven wire coil embolization system, and Swan intravenous RF closure catheter; and the commercialization of relatively new product combinations nationwide, including the Penguin iliac vein stent system and Unicorn vascular closure device. The group's gross profit margin increased from 71.6% in 2024 to 72.1% in 2025, attributed to continuous manufacturing improvements, supply chain optimization, and strategic shift towards high-margin and innovative products. Despite pricing pressures from provincial and national centralized procurement, the group's expansion in sales and production volumes still bring significant cost benefits to its operations and suppliers. The diversified product portfolio further enables the group to optimize marketing efforts to maintain profitability, while its reputation for high-quality products allows the group to price slightly higher than domestic competitors.